Biotech News
Related news
NTLAIntellia2026-10-29 12:00 EST
Intellia Therapeutics Announces Upcoming Lonvoguran Ziclumeran (Lonvo-z) Investor Event and Seven Presentations at ACAAI 2026
NTLAIntellia2026-09-04 12:00 EST
Intellia Therapeutics to Present at Morgan Stanley 24th Annual Global Healthcare Conference
CRSPCRISPR Therapeutics2026-11-10 13:30 EST
CRISPR Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference
CRSPCRISPR Therapeutics2026-09-08 12:30 EST
CRISPR Therapeutics to Present at the Morgan Stanley 24th Annual Global Healthcare Conference
SRPTSarepta Therapeutics2026-08-31 20:30 EST
Sarepta Therapeutics to Present at the Morgan Stanley 24th Annual Global Healthcare Conference
KRYSKrystal Biotech2026-09-03 12:00 EST
Krystal Biotech to Present at 2026 Cantor Global Healthcare Conference
RCKTRocket Pharmaceuticals2026-10-15 11:00 EST
Rocket Pharmaceuticals to Participate in Chardan’s 10th Annual Healthcare Conference
SANASana Biotechnology2026-09-01 20:05 EST
Sana Biotechnology to Present at September 2026 Investor Conferences
MGTXMeiraGTx2026-11-16 12:00 EST
MeiraGTx Announces Oral Presentation at ObesityWeek 2026
CRBUCaribou2026-11-04 14:00 EST
Caribou Biosciences Announces Presentations at the 2026 American Society of Hematology (ASH) Annual Meeting
Intellia
In Vivo CRISPR Gene Editing Intellia Therapeutics develops potentially one-time medicines using CRISPR-based gene editing. Its lead programs edit disease-causing genes directly inside the body through systemically delivered therapies. Hereditary Angioedema Lonvoguran ziclumeran, or lonvo-z, is an in vivo gene-editing candidate designed...
Recent company news
NTLAIntellia2026-11-12 15:00 EST
Intellia Therapeutics Presents Additional Positive Clinical and Patient-Reported Data for Lonvoguran Ziclumeran (lonvo-z) at ACAAI 2026
NTLAIntellia2026-11-10 13:00 EST
Intellia Therapeutics to Present at Jefferies Global Healthcare Conference in London
NTLAIntellia2026-11-06 21:05 EST
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NTLAIntellia2026-11-05 13:00 EST
Intellia Therapeutics Announces Third Quarter 2026 Financial Results and Business Updates
NTLAIntellia2026-11-04 13:00 EST
Intellia Therapeutics Completes Enrollment in Phase 3 MAGNITUDE-2 Trial of Nexiguran Ziclumeran (Nex-z) for Patients with Hereditary Transthyretin Amyloidosis with Polyneuropathy (ATTRv-PN)
Stock data
- Close
- 9.52 USD
- Market cap
- 1.83B USD
- Exchange
- NASDAQ
- Sector
- Biopharma
- Location
- United States
